Concepedia

R. Hindes

RH

Statistics

Publications

24

Citations

5.2K

H-Index

22

Active since

1989

Affiliations

Bristol-Myers Squibb (United States)(Current)

Bristol-Myers Squibb (Germany)

Gilead Sciences (United States)

Hôpital Cochin

Digestive & Liver Disease Specialists

R. Hindes is an author at Bristol-Myers Squibb (United States) specializing in pharmacotherapy, antiviral therapy, and pharmacy.

Publications per year

1989–2014

24

Publications

24

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

Mark Sulkowski, David Gardiner, M. Rodríguez‐Torres et al. · New England Journal of Medicine · 2014 · 1.2K citations

, , +13

Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡

Ting‐Tsung Chang, Yun‐Fan Liaw, Shun-Sheng Wu et al. · Hepatology · 2010 · 988 citations · Full text

, , +17

Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C

Edward Gane, Catherine Stedman, Robert H. Hyland et al. · New England Journal of Medicine · 2013 · 759 citations · Full text

, , +14

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

Morris Sherman, Cihan Yurdaydın, Jose D. Sollano et al. · Gastroenterology · 2006 · 414 citations · Full text

, , +11

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Eric Lawitz, Jay Lalezari, Tarek Hassanein et al. · The Lancet Infectious Diseases · 2013 · 328 citations

, , +16

1–5 of 24